ASSOCIATION BETWEEN SERUM LEVELS OF ADIPOKINES IN PATIENTS WITH PROSTATE CANCER.

Area of Science:

• Endocrinology
• Oncology
• Biochemistry

Background:

• Adipokines are key mediators in obesity-associated cancers.
• Investigating adipokines' role in prostate cancer (PC) is crucial for understanding disease mechanisms.

Purpose of the Study:

• To explore the relationship between adipokines and prostate cancer.
• To assess adipokines as potential early diagnostic and monitoring biomarkers for PC.

Main Methods:

• Study included 82 men (42 with PC, 40 controls).
• PC patients were stratified by Gleason's grading (low, moderate, high).
• Serum levels of adiponectin, resistin, visfatin, and chemerin were measured.

Main Results:

• PC patients exhibited significantly lower adiponectin levels (2.87±0.73 ng/mL) compared to controls (9.9±1.25 ng/mL).
• Resistin, visfatin, and chemerin levels were significantly higher in PC patients than in controls.
• A significant correlation was observed between serum adipokine levels, Prostate-Specific Antigen (PSA), and Body Mass Index (BMI).

Conclusions:

• Adiponectin levels are markedly reduced in PC patients, while other adipokines (resistin, visfatin, chemerin) are elevated.
• The chemerin/adiponectin ratio correlates strongly with PC severity.
• This ratio holds promise as a potential biomarker for early PC detection and treatment response monitoring.